产品
编 号：F454831
分子式：C19H35NO2
分子量：309.49
分子式：C19H35NO2
分子量：309.49
产品类型
规格
价格
是否有货
结构图
CAS No: 77-19-0
产品详情
生物活性：
Dicyclomine (Dicycloverine) is a potent and orally active muscarinic cholinergic receptors antagonist. Dicyclomine (Dicycloverine) shows high affinity for muscarinic M1 receptor subtype (Ki=5.1 nM) and M2 receptor subtype (Ki=54.6 nM) in brush-border membrane and basal plasma membranes, respectively. Dicyclomine is an antispasmodic agent and relieves smooth muscle spasm of the gastrointestinal tract in vivo.
体内研究：
Dicyclomine (Dicycloverine) (intraperitoneal?injection; 8 mg/kg; daily) exacerbates the cognitive impairments in all the measurements. In addition, the memory impairments are worse in dicyclomine-treated 3xTg-AD mice compared to dicyclomine-treated NonTg mice.Dicyclomine (Dicycloverine) (intraperitoneal injection; 2.0, 4.0, and 8.0 mg/kg; 7 days) produces a highly significant effect on performance in the paired-associates learning (PAL) task in mice.And systemic treatment at lower doses show behavioral impairments in mice in spatial tasks.Animal Model:C57Bl/6 mice
Dosage:2.0, 4.0, and 8.0 mg/kg
Administration:Intraperitoneal injection; daily; 7 days
Result:Produced impairments due to actions of the agent outside of the hippocampus.
Dicyclomine (Dicycloverine) is a potent and orally active muscarinic cholinergic receptors antagonist. Dicyclomine (Dicycloverine) shows high affinity for muscarinic M1 receptor subtype (Ki=5.1 nM) and M2 receptor subtype (Ki=54.6 nM) in brush-border membrane and basal plasma membranes, respectively. Dicyclomine is an antispasmodic agent and relieves smooth muscle spasm of the gastrointestinal tract in vivo.
体内研究：
Dicyclomine (Dicycloverine) (intraperitoneal?injection; 8 mg/kg; daily) exacerbates the cognitive impairments in all the measurements. In addition, the memory impairments are worse in dicyclomine-treated 3xTg-AD mice compared to dicyclomine-treated NonTg mice.Dicyclomine (Dicycloverine) (intraperitoneal injection; 2.0, 4.0, and 8.0 mg/kg; 7 days) produces a highly significant effect on performance in the paired-associates learning (PAL) task in mice.And systemic treatment at lower doses show behavioral impairments in mice in spatial tasks.Animal Model:C57Bl/6 mice
Dosage:2.0, 4.0, and 8.0 mg/kg
Administration:Intraperitoneal injection; daily; 7 days
Result:Produced impairments due to actions of the agent outside of the hippocampus.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备